Related Experiment Video

Updated: May 2, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

10.8K

Systemic GLIPR1-ΔTM protein as a novel therapeutic approach for prostate cancer

Theodoros Karantanos1, Ryuta Tanimoto, Kohei Edamura

  • 1Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.

International Journal of Cancer
|March 5, 2014
PubMed

Insights

Recombinant GLIPR1 protein selectively enters prostate cancer cells, inducing apoptosis and inhibiting tumor growth. This novel therapy shows promise with no significant toxicity in mouse models.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • GLIPR1 (glioma pathogenesis-related protein 1) is a p53 target gene downregulated in prostate cancer.
  • Increased GLIPR1 expression correlates with elevated reactive oxygen species (ROS), apoptosis, reduced c-Myc, and cell cycle arrest.
  • Previous work linked GLIPR1 upregulation to mitotic catastrophe via Hsc70 and Aurora kinase A/TPX2 interactions.

Purpose of the Study:

  • To investigate the cellular uptake mechanisms of recombinant GLIPR1 protein (GLIPR1-ΔTM).
  • To evaluate the therapeutic efficacy of systemic GLIPR1-ΔTM administration in a prostate cancer xenograft model.
  • To assess the safety profile of GLIPR1-ΔTM.

Main Methods:

  • Studied the internalization of GLIPR1-ΔTM by prostate cancer cells.
  • Utilized a VCaP xenograft mouse model to assess systemic GLIPR1-ΔTM efficacy.
  • Investigated the role of clathrin-mediated endocytosis and Hsc70 in GLIPR1-ΔTM uptake.
  • Monitored tumor growth and animal toxicity.

Main Results:

  • GLIPR1-ΔTM was selectively internalized by prostate cancer cells.
  • Internalization occurred via clathrin-mediated endocytosis associated with Hsc70.
  • GLIPR1-ΔTM treatment increased ROS production and apoptosis, and decreased c-Myc levels.
  • Systemic GLIPR1-ΔTM significantly inhibited VCaP xenograft growth.
  • No evidence of toxicity was observed 8 hours post-injection.

Conclusions:

  • GLIPR1-ΔTM is selectively endocytosed by prostate cancer cells, mediating apoptosis through ROS induction.
  • Systemic administration of GLIPR1-ΔTM effectively inhibits prostate cancer xenograft growth.
  • GLIPR1-ΔTM demonstrates a favorable safety profile with minimal toxicity.
Keywords:
GLIPR1prostate cancerprotein therapy

More Related Videos

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

28.7K
An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.3K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121